Neoantigen Targeted Therapies Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Neoantigen targeted therapies represent a precision oncology approach that harnesses tumor-specific mutations to stimulate personalized immune responses against cancer cells. The market encompasses three primary segments: personalized neoantigen cancer vaccines, adoptive cell therapies, and mRNA-based therapeutic platforms. With a 2025 baseline of approximately $0.94 billion, the market is positioned for robust expansion driven by technological maturation and increasing clinical evidence supporting personalized immunotherapy approaches.

• •Personalized cancer vaccines lead the market, utilizing patient-specific tumor sequencing to design individualized treatment regimens
• •Adoptive cell therapy approaches, including engineered T-cell therapies, form a significant therapeutic modality within this space
• •Next-generation sequencing and computational biology platforms form the foundational infrastructure enabling neoantigen identification and characterization

The market expansion is propelled by the convergence of precision medicine advances, rising global cancer incidence, and decreasing costs of genomic sequencing technologies. Artificial intelligence and machine learning algorithms are accelerating neoantigen prediction accuracy, while streamlined manufacturing processes are improving the commercial viability of personalized therapies. Regulatory pathways are evolving to accommodate the unique challenges of individualized therapeutic products.

• •Artificial intelligence-powered antigen prediction tools are dramatically reducing the time and cost of identifying actionable neoantigens from tumor genomic data
• •The rising global cancer burden and shift toward precision oncology approaches create sustained demand for personalized treatment modalities
• •Advances in next-generation sequencing and declining genomic analysis costs have made personalized neoantigen identification increasingly accessible and scalable

The market is segmented into personalized cancer vaccines, adoptive cell therapy, and mRNA-based therapeutics, with personalized vaccines representing the largest and fastest-growing segment. North America dominates the regional landscape, supported by advanced healthcare infrastructure, substantial R&D investment, and favorable regulatory frameworks for personalized medicine. Asia-Pacific is emerging as a high-growth region driven by expanding clinical research activities and improving healthcare access.

• •North America commands the largest market share, with the United States leading in clinical trial activity and commercial development of neoantigen therapies
• •Personalized cancer vaccines based on peptide and mRNA platforms represent the dominant technology segment, with dendritic cell approaches also gaining traction
• •Europe and Asia-Pacific are experiencing accelerated growth as genomic profiling capabilities expand and clinical research infrastructure matures across these regions

What are the recent trends and outlook?

The market is positioned for sustained growth through 2035 as clinical evidence accumulates and regulatory frameworks mature to support personalized therapeutic products. Integration of multi-omics data and advanced computational methods will further refine neoantigen prediction and patient selection strategies. Combination therapies pairing neoantigen vaccines with checkpoint inhibitors or other immuno-oncology agents represent a particularly promising near-term development area.

• •Combination therapy approaches pairing neoantigen vaccines with immune checkpoint inhibitors are showing enhanced clinical efficacy in ongoing trials
• •AI and machine learning integration is expected to significantly improve neoantigen identification accuracy and reduce development timelines
• •Manufacturing process standardization and decentralized production models are emerging to address scalability challenges inherent in personalized medicine approaches